Deepro nebulizer maker HCmed has announced that Vivo Capital’s PANDA Fund has become a strategic investor as of December 27, 2017, saying, “As a healthcare focused investment firm, Vivo will fully support HCmed’s strategic plan to expand in the hand-held nebulizer markets to help relive [sic] global burden of respiratory disease, such as COPD, asthma and cystic fibrosis.” The amount of the investment was not disclosed.
The company launched Deepro in 2016, exhibiting the device at DDL 27. According to HCmed it has partnered with pharmaceutical companies in the US, China, Israel, Indonesia, India, Latin America and Taiwan on the handheld vibrating mesh nebulizer.
Read the HCmed press release.
